Charles River Laboratories International, Inc. (NYSE: CRL), a provider of products and services for pharma companies to accelerate drug discovery and development efforts, on Wednesday reported stronger-than-expected revenue and adjusted earnings for the fourth quarter of fiscal 2025.
Fourth-quarter revenue declined 0.8% to $994.2 million from $1.0 billion in the comparable period of FY24. However, the top-line came in above Wall Street’s expectations.
On an adjusted basis, Q4 earnings declined 10.2% year-over-year to $2.39 per share, but beat analysts’ forecasts. On an unadjusted basis, it was a net loss of $276.6 million or $5.62 per share, compared to a loss of $215.7 million or $4.22 per share in the prior-year quarter.
For fiscal 2026, management expects revenue to be flat to up 1.5% compared to FY25. Full-year organic revenue is expected to be down 1% to at least flat. The guidance for reported earnings per share is $6.30-$6.80. On an unadjusted basis, earnings are expected to be in the range of $10.70 to $11.20 in FY26.
James Foster, chief executive officer of the company, said, “As we look ahead, we are cautiously optimistic that positive demand trends will continue in 2026. We remain committed to driving our strategy forward, including through selective and strategic acquisitions that align with our core competencies; taking decisive actions to drive efficiency and process improvements that will deliver continued benefits; and by strengthening and refining our organization to enhance our speed and responsiveness.”